BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34118831)

  • 1. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.
    Fan Y; Qin J; Han N; Lu H
    Ann Palliat Med; 2022 Apr; 11(4):1582-1588. PubMed ID: 34118831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
    BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report.
    Ma Y; Liu H; Zhang M; Liu B; Ding Q; Zhang L; Guo L; Liu M
    Ann Palliat Med; 2022 Apr; 11(4):1533-1541. PubMed ID: 34263612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
    Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
    Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
    Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
    Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poziotinib in Non-Small-Cell Lung Cancer Harboring
    Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
    J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
    Huang X; Yang Y; Wang P; Han-Zhang H; Ding L
    Ann Palliat Med; 2021 Jun; 10(6):6997-7002. PubMed ID: 33183015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting
    Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
    Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
    Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.
    Nie N; Zhou H; Zhang K; Liu L; Luo N; Wang R; Li X; Zhu M; Hu C; Wang Y; Liu Z; Li L; He Y
    Thorac Cancer; 2022 Sep; 13(18):2574-2583. PubMed ID: 35896160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].
    Li H; Xie Y; Lin Y; Yu T; Yin Z
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):646-654. PubMed ID: 32838487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
    Tsuchiya K; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
    Intern Med; 2018 Dec; 57(23):3423-3427. PubMed ID: 30101917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
    Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
    Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
    Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
    Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
    Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of Clinicopathological Feature and Prognosis for 
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
    Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
    Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.